Long-term therapy outcomes of CD19/22 CAR T-cell alone or with autologous stem cell transplantation for relapsed/refractory DLBCL.

Authors

Xiaoying Zhang, Jue Wang, Na Wang, Yang Yang, Jinhuan Xu, Xiaojian Zhu, Gaoxiang Wang, Di Wang, Fankai Meng, Yi Xiao, Miao Zheng, Li Meng, Chunrui Li, Jia Wei, Yang Cao, Yicheng Zhang

Published in

Blood cancer discovery. Oct 24, 2025. Epub Oct 24, 2025.

Abstract

We conducted a comparative analysis of the long-term efficacy and safety of two single-arm trials for relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL): CD19/CD22 chimeric antigen receptor (CAR19/22) T-cell cocktail therapy alone (Trial A) or combined with autologous stem cell transplantation (ASCT) (Trial B). The study included 124 patients not in remission after bridging therapy. Cytopenia (36.92% vs.52.54%) and infection (29.68% vs. 28.81%) were the predominant late grade ≥3 adverse events. Trial B achieved higher overall response rate (best overall response: 93.22% vs. 78.46%, P=0.023) and superior progression-free survival (PFS) (median, 5.68 months vs. not reaching, P<0.001) and overall survival (OS) (median, 27.61 months vs. not reaching, P<0.001) than Trial A. Independent predictors of longer PFS and OS included achieving complete response at 3 months and receiving combination therapy. The associations remained statistically significant after adjustment in sensitivity analyses incorporating propensity score matching and inverse probability of treatment weighting.

PMID:
41133959
Bibliographic data and abstract were imported from PubMed on 24 Oct 2025.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.